-
International Journal of Nephrology and Renovascular Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension
Review
(1596) Views (481) Full article downloads
Authors: Michel E Safar
Published Date December 2010
Volume 2010:3 Pages 167 - 174
DOI: http://dx.doi.org/10.2147/IJNRD.S6664
Michel E SafarUniversité Paris Descartes, Assistance Publique-Hôpitaux de Paris, Hôtel-Dieu Centre de Diagnostic et de Thérapeutique, Paris, France
Abstract: In hypertension, the blood pressure curve may be divided into two sets of components. The first set is mean arterial pressure, steady flow, and vascular resistance, thus acting on small arteries; the second set refers to large arteries, hence to pulse pressure, arterial stiffness, and wave reflections. The angiotensin-converting enzyme (ACE) inhibitor perindopril not only reduces mean arterial pressure but also acts specifically on pulse pressure. The effect on pulse pressure predominates on central rather than peripheral (brachial) large arteries, reducing aortic stiffness and most wave reflections. Such hemodynamic changes are not observed with standard ß-blockade, which reduces aortic stiffness and brachial systolic and pulse pressure but not central pulse pressure and wave reflections. In hypertensive subjects, perindopril and other ACE inhibitors seem to predict more consistently the reduction of cardiovascular events, mainly of cardiac origin, than standard ß-blockers alone. This effect is associated with the important biochemical finding that mechanotransductions of angiotensin and ß-blockade are markedly different, acting in the former specifically on the α5ß1 integrin complex and on the fibronectin ligand of arterial vessels.
Keywords: antihypertensive therapy, arterial stiffness, renal function
Other articles by Professor Michel Safar
Readers of this article also read:
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Update on the diagnosis and management of acute kidney injury
New and improved strategies for the treatment of gout
Community-based health efforts for the prevention of falls in the elderly
VEGF 936C>T is predictive of threshold retinopathy of prematurity in Japanese infants with a 30-week gestational age or less
Personal best times in an Olympic distance triathlon and in a marathon predict Ironman race time in recreational male triathletes
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Emerging drug combinations to optimize renovascular protection and blood pressure goals
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Potential renovascular hypertension, space missions, and the role of magnesium
- The use of everolimus in renal-transplant patients
- Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate




